中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2009年
3期
177-179
,共3页
陈河香%王向阳%王舜钦%何洪涛%罗小光%陈小刚%林潮双
陳河香%王嚮暘%王舜欽%何洪濤%囉小光%陳小剛%林潮雙
진하향%왕향양%왕순흠%하홍도%라소광%진소강%림조쌍
粒细胞-巨噬细胞集落刺激因子%肝炎疫苗,乙型%佐剂,免疫%免疫减弱宿主
粒細胞-巨噬細胞集落刺激因子%肝炎疫苗,乙型%佐劑,免疫%免疫減弱宿主
립세포-거서세포집락자격인자%간염역묘,을형%좌제,면역%면역감약숙주
Granulocyte-macrophage colong-stimulating factor%Hepatitis B vaccines%Adjuvants immunologic%Immunecompromised host
目的 探讨重组人粒细胞.巨噬细胞集落刺激因子(rhGM-CSF)对提高成人乙肝疫苗无(弱)应答免疫的作用.方法 将两年内完成1~2个标准乙肝疫苗接种程序、复查HBV标志物均阴性的健康人群随机分为A、B两组.A组:33人,按标准免疫程序予10μg乙肝疫苗;B组:34人,先予rhGM-CSF 300μg皮下注射,次日始按A组方案予乙肝疫苗.接种首针后第1、2、8个月(T1、T2、T8)采血检测抗-HBs.结果 A、B组T8抗-HBs阳性率分别为39.39%和64.71%(P=0.038);A组三次抗体滴度检测结果 无显著性变化;B组升高明显,分别为(113.85±198.56)mIU/ml,(312.40±349.44)mIU/ml,(427.74±411.58)mIU/ml(P=0.001).A组和B组T8抗体水平差异有统计学意义(P=0.010).结论 rhGM-CSF联合乙肝疫苗复种对无(弱)应答者免疫效果优于单纯复种,GM-CSF具有提高机体对乙肝疫苗免疫应答的能力.
目的 探討重組人粒細胞.巨噬細胞集落刺激因子(rhGM-CSF)對提高成人乙肝疫苗無(弱)應答免疫的作用.方法 將兩年內完成1~2箇標準乙肝疫苗接種程序、複查HBV標誌物均陰性的健康人群隨機分為A、B兩組.A組:33人,按標準免疫程序予10μg乙肝疫苗;B組:34人,先予rhGM-CSF 300μg皮下註射,次日始按A組方案予乙肝疫苗.接種首針後第1、2、8箇月(T1、T2、T8)採血檢測抗-HBs.結果 A、B組T8抗-HBs暘性率分彆為39.39%和64.71%(P=0.038);A組三次抗體滴度檢測結果 無顯著性變化;B組升高明顯,分彆為(113.85±198.56)mIU/ml,(312.40±349.44)mIU/ml,(427.74±411.58)mIU/ml(P=0.001).A組和B組T8抗體水平差異有統計學意義(P=0.010).結論 rhGM-CSF聯閤乙肝疫苗複種對無(弱)應答者免疫效果優于單純複種,GM-CSF具有提高機體對乙肝疫苗免疫應答的能力.
목적 탐토중조인립세포.거서세포집락자격인자(rhGM-CSF)대제고성인을간역묘무(약)응답면역적작용.방법 장량년내완성1~2개표준을간역묘접충정서、복사HBV표지물균음성적건강인군수궤분위A、B량조.A조:33인,안표준면역정서여10μg을간역묘;B조:34인,선여rhGM-CSF 300μg피하주사,차일시안A조방안여을간역묘.접충수침후제1、2、8개월(T1、T2、T8)채혈검측항-HBs.결과 A、B조T8항-HBs양성솔분별위39.39%화64.71%(P=0.038);A조삼차항체적도검측결과 무현저성변화;B조승고명현,분별위(113.85±198.56)mIU/ml,(312.40±349.44)mIU/ml,(427.74±411.58)mIU/ml(P=0.001).A조화B조T8항체수평차이유통계학의의(P=0.010).결론 rhGM-CSF연합을간역묘복충대무(약)응답자면역효과우우단순복충,GM-CSF구유제고궤체대을간역묘면역응답적능력.
Objective To investigate the effect of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) as adjuvant on immune response in adults of non-and hyporesponders to hepatitis B vaccine. Methods Those who were once immunized with recombined yeast gene hepatitis B vaccine more than one standard scheme in two years and negative for hepatitis B markers were randomly sorted as group A and group B. 33 adults of group A were given hepatitis B vaccine 10 μg each time. The immune procedure was O, 1 and 6month. 34 adults of group B were given rhGM-CSF 300 μg for the first day, then 10 μg each time for routine immune. The blood samples were collected before the first injection and in 1, 2 and 8 months (T1, T2, TS)following the first injection to test Anti-HBs. Results Anti-HBs positive conversion rates of group A and B at T8 was 39.39% and 64.71% respectively(P=0.038). Anti-HBs levels of group B at TI, T2, T8 were(113.85±198.56) mIU/ml, (312.40±349.44) mIU/ml, (427.74±411. 58) mIU/ml (P=0.001). There was significant difference between group A and B in T8 Anti-HBs levels(P=0.010). Conclusion Better immune response was found in the group of rhGM-CSF with hepatitis B vaccine. So rhGM-CSF can induce the immune respond to hepatitis B vaccine.